FDA approves first mRNA vaccine for seasonal flu

Gloved hands draw fluid from a vaccine vial into a syringe.

The U.S. Food and Drug Administration (FDA) has approved a new seasonal flu vaccine that uses mRNA as its base.

Moderna, the vaccine's maker, announced Wednesday (Aug. 5) that a vaccine advisory committee to the FDA unanimously agreed that the shot is safe and effective for preventing illness from seasonal influenza. The shot, called mFlusiva or mRNA-1010, has been approved for people ages 50 and older.